网站大量收购独家精品文档,联系QQ:2885784924

慢性乙肝抗病毒治疗ppt课件.pptVIP

  1. 1、本文档共32页,可阅读全部内容。
  2. 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
  3. 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  4. 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
  5. 5、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
  6. 6、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们
  7. 7、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
  8. 8、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
慢性乙肝抗病毒治疗ppt课件

对患者和携带者的管理 - 对慢性HBV携带者及HBsAg携带者,除不能献血和 国家法律规定不能从事的特殊职业(如服兵役等) 以外,可照常生活、学习和工作,但要加强随访 - 乙肝患者和携带者的传染性,主要取决于血液中 HBV DNA水平,与血清ALT/AST或胆红素水平无关 预防 欢 迎 指 正 Key message Progression of hepatitis B is variable. Acute hepatitis B is usually self limiting and benign, but may progress to chronic hepatitis B in a proportion of patients. Chronic hepatitis B may lead to more serious conditions including cirrhosis, liver failure and hepatocellular carcinoma. Points of explanation In the liver, acute infection (short term infection) with hepatitis B causes the body to mount an immune response to eliminate the virus. The immune system attempts to eradicate the virus by destroying HBV infected liver cells. In some patients the immune response succeeds and the patient makes a complete recovery (resolution). However in other HBV-infected people, the immune response to the infection is insufficient to eliminate the virus for many months / years or not at all; slowly destroying more and more infected liver cells as the virus spreads (long-term infection). This slow persistent destruction of liver cells by the immune system can lead to fibrosis, cirrhosis and even hepatocellular carcinoma. Patients infected with HBV whose immune systems cannot eliminate the virus are referred to as chronic HBV carriers. Chronic HBV carriers can pass the virus to others. Hepatitis B surface antigen (HBsAg) is the first serological marker to appear in the serum and is present in high levels during acute and chronic infection. Persistence of HBsAg for more than 6 months defines a chronic infection. References Feitelson MA. Biology of disease: biology of hepatitis B virus mutants. Lab Invest 1994; 71: 324-349. 慢乙肝治疗的主要目标是清除或永久性抑制乙肝病毒。由此可以降低致病作用与感染性,从而中止或减少了肝脏的坏死炎症。在临床上,治疗的短期目标是减轻肝脏的炎症,防止肝脏纤维化和/或肝脏失代偿的发生,能持续保持HBVDNA消失,和丙氨酸氨基转移酶(ALT)的正常。治疗的长期目标则是避免ALT的活动及导致的肝脏失代偿,以及预防肝硬化和/或肝细胞肝癌(HCC)的发生,最终延长生存期。 理想的治疗终点(HBeAg阳性及HBeAg阴性患者): 满意的治疗终点(HBeAg阳性患者): 其次的治疗终点(不能实现HBeAg血清转换的 HBeAg阳性患者和HBeAg阴性患者)

文档评论(0)

wuyoujun92 + 关注
实名认证
文档贡献者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档